All In Biotech

Drug Trial Radar · NCT03414008

This Study Tests How Different Doses of BI 1291583 Are Taken up in the Body and How Well They Are Tolerated

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 1291583 (Single-blind, Partially Randomised, Placebo-controlled Parallel Group Design) in Healthy Male Subjects

Last checked: Nov 19, 2026Latest source record: Aug 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

54

Actual

Start

Feb 5, 2018

Primary completion

Nov 18, 2019

Study completion Nov 18, 2019

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Jan 29, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary objective of this trial is to investigate the safety and tolerability of BI 1291583 in healthy male subjects following oral administration of single rising doses. Secondary objectives are the exploration of the pharmacokinetics (PK) including dose proportionality and pharmacodynamics (PD) of BI 1291583 after single dosing.

Conditions

  • Healthy

Interventions

  • BI 1291583Drug

    Single dose

  • Matching placebo: Tartaric acidDrug

    Single dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Assess safety and tolerability of BI 1291583 is the number [N (%)] of subjects with drug-related adverse eventsTime frame: up to 120 hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Humanpharmakologisches Zentrum Biberach

    Biberach, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.